SCHEMBL7070199

SCHEMBL7070199

CCC1(C(=O)O)CC1c1ccc(OC)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
RAB9A P51151 1/20 0.45
ALDH1A1 P00352 5/20 0.43
LMNA P02545 3/20 0.43
GAA P10253 3/20 0.43
HPGD P15428 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TSHR P16473 3/20 0.40
CYP2C9 P11712 1/20 0.40
BLM P54132 1/20 0.40
PPARA Q07869 1/20 0.40
EDNRA P25101 2/20 0.40
EDNRB P24530 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
RECQL P46063 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CA1 P00915 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21501076 0.82 RAB9A (0.46) KMT2AMEN1RAB9AALDH1A1GAA
SCHEMBL21501027 0.82 RAB9A (0.46) KMT2AMEN1RAB9AALDH1A1GAA
SCHEMBL1943935 0.82 KDM1A (0.51) GAASMN1; SMN2
SCHEMBL15767640 0.82 KDM1A (0.51) GAASMN1; SMN2
SCHEMBL11700667 0.82 KDM1A (0.51) GAASMN1; SMN2
SCHEMBL7077980 0.81 KDM1A (0.51) LMNATSHRCYP2C9BLMPPARA
SCHEMBL3739337 0.81 KDM1A (0.40) LMNAGAASMN1; SMN2
SCHEMBL15766918 0.81 KDM1A (0.51) KMT2AMEN1ALDH1A1LMNAGAA
SCHEMBL15766917 0.81 KDM1A (0.51) KMT2AMEN1ALDH1A1LMNAGAA
SCHEMBL1000359 0.81 KDM1A (0.51) KMT2AMEN1ALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296938-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE Pfizer Limited (GB) 2003-04-02 EP disclosed
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER, INC. 2002-05-02 US disclosed
WO-2002002513-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE PFIZER LIMITED (GB) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase ENGASE, ENPEP, CPN1 KMT2A 3282/4885MEN1 2636/4885RAB9A 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.